Publications by authors named "Francisco J Manero-Ruiz"
Anti-TNFα drug levels in patients with rheumatoid arthritis and spondyloarthritis.
Reumatol Clin (Engl Ed)
October 2022
Article Synopsis
- - This study evaluates the levels of anti-TNFα drugs in patients with rheumatoid arthritis (RA) compared to those with spondyloarthritis (SpA), aiming to understand how treatment can be adjusted based on these levels.
- - A retrospective analysis was conducted on patients using infliximab, adalimumab, and etanercept, measuring drug levels and the presence of anti-drug antibodies through the ELISA technique.
- - The findings revealed that while drug levels varied among different medications and were influenced by the use of DMARDs, they remained unaffected by the overall activity of the diseases being treated.
Anti-TNFα Drug Levels in Patients with Rheumatoid Arthritis and Spondyloarthritis.
Reumatol Clin (Engl Ed)
September 2021
Article Synopsis
- A study was conducted to compare anti-TNFα drug levels in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) to see how treatment might be modified based on these levels.
- The research involved analyzing drug levels and the presence of anti-drug antibodies in patients receiving infliximab, adalimumab, and etanercept, using a specific testing method (ELISA).
- Findings revealed that while drug levels didn't vary significantly with disease activity, they did differ based on whether patients were also taking DMARDs.
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Rheumatology (Oxford)
November 2021
Article Synopsis
- SLE (Systemic Lupus Erythematosus) significantly affects the gastrointestinal tract, with over 50% of patients reporting GI symptoms; a study analyzed data from 3658 SLE patients to understand these manifestations.
- Patients with GI damage (3.7% of the cohort) were generally older, had longer disease duration, and higher rates of complications like vasculitis and renal disease, leading to increased hospitalizations and mortality.
- The presence of GI damage correlates with worse prognosis, and higher glucocorticoid doses increase the risk, while oral ulcers may actually reduce the likelihood of developing GI damage.
Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up.
Rheumatology (Oxford)
June 2021
Objectives: To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up.
Methods: This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n = 775), AS (n = 738) and PsA (n = 721), and individuals without CIRD (n = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain.
Objective: To compare the safety and retention rate of TNF antagonists used in approved indications (AIs) and non-AIs.
Methods: Analysis of the Spanish registry BIOBADASER 2.0 (February 2000 to October 2009).
Background And Objective: Knowing the differences in the effectiveness between three tumour necrosis factor alpha antagonists (anti-TNF alpha) in rheumatoid arthritis (RA) has important clinical implications. The aim of this study was to assess anti-TNF alpha effectiveness and to study possible differences in outcomes between them.
Patients And Method: We included all patients with rheumatoid arthritis (RA) attended in consulting room from Zaragoza Area II between May 2000 and December 2006 who completed a year with anti-TNF alpha treatment.